Role of Interval Reduction of Somatostatin Analogs in Patients with Progressive Neuroendocrine Tumors: Our Experience

#2232

Introduction: Interval reduction of somatostatin analogs (SSAs) is a possibly strategy for elderly patients with progressive metastatic neuroendocrine tumors (NETs). Patients with diagnosis of NET are >75 years old in the 25% of cases. No randomized studies are available to evaluate efficacy of this treatment schedule.

Aim(s): Evaluate interval reduction of SSAs in progressive NETs in the elderly.

Materials and methods: We evaluated 6 patients with progressive NETs receiving Lanreotide ATG 120 mg/21 days.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Puliafito I, Prestifilippo A, Colarossi C, Giuffrida P, Castorina L,

Keywords: somatostatin, analogs, interval, reduction, experience, elderly,